Chiasma has completed an international Phase 3 trial of Mycapssa® (octreotide) capsules, the results of which have been published in the Journal of Clinical Endocrinology and Metabolism. The company is now conducting an additional international Phase 3 trial of Mycapssa in acromegaly designed to support a potential Marketing Authorization Application with the European Medicines Agency.